What is the price target for BTTX stock?
8 analysts have analysed BTTX and the average price target is 5.36 USD. This implies a price increase of 11906.73% is expected in the next year compared to the current price of 0.0446.
BETTER THERAPEUTICS INC (BTTX) Forecast, Price Target & Analyst Ratings
NASDAQ:BTTX • US08773T1043
Current stock price
0.0446 USD
+0.01 (+27.43%)
At close:
0.036 USD
-0.01 (-19.28%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BETTER THERAPEUTICS INC (BTTX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 27, 2024
- Period
- Q4 / 2023
- EPS Estimate
- -$0.12
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$5.36
Upside
+ 11,906.73%
From current price of $0.04 to mean target of $5.36, Based on 8 analyst forecasts
Low
$1.52
Median
$5.36
High
$9.45
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for BTTX. The average price target is 5.36 USD. This implies a price increase of 11906.73% is expected in the next year compared to the current price of 0.0446.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
BTTX was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about BTTX.
In the previous month the buy percentage consensus was at a similar level.
BTTX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-08-10 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-08-10 | Lake Street | Maintains | Buy -> Buy |
| 2023-04-14 | Lake Street | Maintains | Buy |
| 2023-03-31 | Chardan Capital | Maintains | Buy |
| 2022-11-15 | Chardan Capital | Maintains | Buy |
| 2022-07-29 | Chardan Capital | Maintains | Buy |
| 2021-11-24 | Chardan Capital | Initiate | Buy |
| 2021-11-10 | Cowen & Co. | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 27, 2024
- Period
- Q4 / 2023
- EPS Estimate
- -$0.12
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 66.92%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
BTTX is expected to report earnings on 3/27/2024. The consensus EPS estimate for the next earnings is -0.12 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2023 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 12.56% | N/A 258.65% | N/A 192.68% | N/A 3,293.09% | N/A 27.99% | N/A 12.87% | ||||
| EBITDA YoY % growth | N/A | -28.94M | -35.53M -22.77% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -30.56M | -38.26M -25.20% | N/A 27.75% | N/A -75.65% | N/A 33.24% | N/A 38.30% | N/A 38.16% | N/A 4,745.72% | N/A 47.33% | N/A 21.44% | ||
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -1.68 49.05% | N/A 50.82% | N/A -23.46% | N/A -8.00% | N/A 36.11% | N/A 34.78% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.12 66.92% | -0.21 45.08% | -0.20 17.12% | -0.20 -36.00% | -0.20 -62.50% | -0.28 -28.57% | -0.26 -28.21% | -0.24 -20.00% | -0.22 -12.82% |
| Revenue Q2Q % growth | 69.36K | 174.93K | 236.64K | 294.27K | 2.101M 2,929.12% | 2.663M 1,422.32% | 3.258M 1,276.77% | 3.885M 1,220.22% | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -5.916M 28.89% | -7.387M 17.28% | -7.519M -6.96% | -7.59M -42.10% | -8.208M -38.74% | -6.232M 15.63% | -5.847M 22.25% | -5.432M 28.44% | -4.986M 39.26% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
10.36%
EPS Next 5 Year
11.54%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
922.61%
Revenue Next 5 Year
545.71%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
BETTER THERAPEUTICS INC / BTTX Forecast FAQ
When does BETTER THERAPEUTICS INC (BTTX) report earnings?
BETTER THERAPEUTICS INC (BTTX) will report earnings on 2024-03-27, after the market close.
What are the consensus estimates for BTTX stock next earnings?
The consensus EPS estimate for the next earnings of BETTER THERAPEUTICS INC (BTTX) is -0.12 USD and the consensus revenue estimate is 0 USD.
What is the expected long term growth rate for BETTER THERAPEUTICS INC (BTTX)?
The expected long term growth rate for BETTER THERAPEUTICS INC (BTTX) is 922.61%.